Retour

Travere Therapeutics to Present at Upcoming Investor Conferences

Calendar Calendar of Events

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

GlobeNewswire Inc. • 08/05/2024 à 22:30:00
Travere Therapeutics, Inc. Common Stock
Address: 3611 VALLEY CENTRE DR
Postal Code: 92130
City: SAN DIEGO
State: CA
Phone Number: 888-969-7879
Website: https://www.travere.com
Status: Active
Company Info

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

List Date2003-07-23
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001438533
Composite figiBBG000P9D6W9
Share Class figiBBG001SL72C5
Market Cap461,341,849 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees380
Share Class Shares Outstanding76130000
Weighted Shares Outstanding76129018
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
6.215
6.695
6.965
6.7
6.25
Variance
-7.17%
-3.88%
4.31%
5.4%
-0.79%
Open
6.695
6.965
6.677
6.357
6.3
Highest
6.71
6.965
7.179
6.895
6.584
Lowest
6.706
6.939
7.154
6.895
6.543
History
PeriodVarhighestlowest
1 week
-1.35%
6.584
6.543
1 month
9.79%
5.92
5.517
3 month
-23.24%
8.36
5.517
6 month
5.52%
5.92
5.517
1 year
-63.03%
16.95
5.25
3 year
-65.91%
18.55
5.25
5 year
-75.63%
25.5
5.25
10 year
-75.63%
25.5
5.25
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Assets 808,231,000 736,429,000 832,850,000 UNPUB
Current Assets 604,904,000 542,055,000 686,230,000 UNPUB
Current Liabilities 130,645,000 135,711,000 139,433,000 UNPUB
Equity 189,140,000 116,485,000 279,766,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 189,140,000 116,485,000 279,766,000 UNPUB
Liabilities 619,091,000 619,944,000 553,084,000 UNPUB
Liabilities And Equity 808,231,000 736,429,000 832,850,000 UNPUB
Noncurrent Assets 203,327,000 194,374,000 146,620,000 UNPUB
Noncurrent Liabilities 488,446,000 484,233,000 413,651,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Exchange Gains/Losses 848,000 82,000 -180,000 UNPUB
Net Cash Flow 99,688,000 -90,502,000 73,370,000 UNPUB
Net Cash Flow, Continuing 98,840,000 -90,584,000 -182,937,000 UNPUB
Net Cash Flow From Financing Activities 216,996,000 2,266,000 -634,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 216,996,000 2,266,000 489,000 UNPUB
Net Cash Flow From Investing Activities -37,039,000 -23,553,000 133,318,000 UNPUB
Net Cash Flow From Investing Activities, Continuing -37,039,000 -23,553,000 -72,856,000 UNPUB
Net Cash Flow From Operating Activities -81,117,000 -69,297,000 -59,134,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -81,117,000 -69,297,000 -110,570,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Comprehensive Income/Loss -85,600,000 -87,309,000 150,937,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -85,600,000 -87,309,000 150,937,000 UNPUB
Other Comprehensive Income/Loss -85,600,000 -87,309,000 150,937,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-04 2023-08-03 2023-11-07 UNPUB
Basic Earnings Per Share -1 -1 2 UNPUB
Benefits Costs and Expenses 143,246,000 145,262,000 126,324,000 UNPUB
Cost Of Revenue 5,125,000 1,990,000 1,289,000 UNPUB
Costs And Expenses 144,039,000 147,278,000 129,680,000 UNPUB
Diluted Earnings Per Share -1 -1 2 UNPUB
Gross Profit 51,868,000 57,707,000 35,806,000 UNPUB
Income/Loss From Continuing Operations After Tax -86,331,000 -85,630,000 -89,241,000 UNPUB
Income/Loss From Continuing Operations Before Tax -86,253,000 -85,565,000 -89,229,000 UNPUB
Income Tax Expense/Benefit 78,000 65,000 12,000 UNPUB
Interest Expense, Operating 2,900,000 2,900,000 2,800,000 UNPUB
Net Income/Loss -86,331,000 -85,630,000 150,735,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -86,331,000 -85,630,000 150,735,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -86,331,000 -85,630,000 150,735,000 UNPUB
Operating Expenses 138,914,000 145,288,000 128,391,000 UNPUB
Operating Income/Loss -87,046,000 -87,581,000 -92,585,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 56,993,000 59,697,000 37,095,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-04 2022-10-27 2023-02-23
Assets 828,405,000 779,494,000 726,215,000 672,585,000
Current Assets 631,093,000 586,777,000 534,842,000 486,437,000
Current Liabilities 119,473,000 124,492,000 131,032,000 142,163,000
Equity 208,141,000 156,713,000 100,676,000 42,851,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 208,141,000 156,713,000 100,676,000 42,851,000
Liabilities 620,264,000 622,781,000 625,539,000 629,734,000
Liabilities And Equity 828,405,000 779,494,000 726,215,000 672,585,000
Noncurrent Assets 197,312,000 192,717,000 191,373,000 186,148,000
Noncurrent Liabilities 0 0 494,507,000 487,571,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-04 2022-10-27 2023-02-23
Exchange Gains/Losses -939,000 -1,742,000 -1,254,000 -2,794,000
Net Cash Flow 90,819,000 -76,813,000 -28,422,000 -104,065,000
Net Cash Flow, Continuing 91,758,000 -75,071,000 -27,168,000 -101,271,000
Net Cash Flow From Financing Activities 113,913,000 831,000 2,278,000 117,573,000
Net Cash Flow From Financing Activities, Continuing 113,913,000 831,000 2,278,000 117,573,000
Net Cash Flow From Investing Activities 33,165,000 -39,096,000 10,079,000 -32,553,000
Net Cash Flow From Investing Activities, Continuing 33,165,000 -39,096,000 10,079,000 -32,553,000
Net Cash Flow From Operating Activities -55,320,000 -36,806,000 -39,525,000 -186,291,000
Net Cash Flow From Operating Activities, Continuing -55,320,000 -36,806,000 -39,525,000 -186,291,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-04 2022-10-27 2023-02-23
Comprehensive Income/Loss -77,104,000 -66,419,000 -68,271,000 -280,827,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -77,104,000 -66,419,000 -68,271,000 -280,827,000
Other Comprehensive Income/Loss -77,104,000 -66,419,000 -68,271,000 -280,827,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-05 2022-08-04 2022-10-27 2023-02-23
Basic Earnings Per Share -1 -1 -1 -4
Benefits Costs and Expenses 124,406,000 121,146,000 123,007,000 490,187,000
Cost Of Revenue 2,138,000 2,051,000 1,675,000 7,592,000
Costs And Expenses 114,617,000 119,618,000 121,630,000 478,584,000
Diluted Earnings Per Share -1 -1 -1 -4
Gross Profit 46,349,000 52,116,000 51,821,000 204,426,000
Income/Loss From Continuing Operations After Tax -75,971,000 -67,032,000 -69,656,000 -278,482,000
Income/Loss From Continuing Operations Before Tax -75,919,000 -66,979,000 -69,511,000 -278,169,000
Income Tax Expense/Benefit 52,000 53,000 145,000 313,000
Interest Expense, Operating UNPUB UNPUB UNPUB 11,300,000
Net Income/Loss -75,971,000 -67,032,000 -69,656,000 -278,482,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -75,971,000 -67,032,000 -69,656,000 -278,482,000
Net Income/Loss Available To Common Stockholders, Basic -75,971,000 -67,032,000 -69,656,000 -278,482,000
Operating Expenses 112,479,000 117,567,000 119,955,000 470,992,000
Operating Income/Loss -66,130,000 -65,451,000 -68,134,000 -266,566,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 48,487,000 54,167,000 53,496,000 212,018,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-29 2021-10-29 2022-02-24
Assets 764,045,000 746,766,000 775,075,000 776,633,000
Current Assets 565,040,000 549,798,000 579,079,000 582,827,000
Current Liabilities 85,013,000 96,977,000 113,163,000 124,088,000
Equity 362,689,000 332,303,000 307,370,000 302,112,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 362,689,000 332,303,000 307,370,000 302,112,000
Liabilities 401,356,000 414,463,000 467,705,000 474,521,000
Liabilities And Equity 764,045,000 746,766,000 775,075,000 776,633,000
Noncurrent Assets 199,005,000 196,968,000 195,996,000 193,806,000
Noncurrent Liabilities 0 0 354,542,000 350,433,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-29 2021-10-29 2022-02-24
Exchange Gains/Losses -113,000 64,000 42,000 1,713,000
Net Cash Flow 63,460,000 -64,944,000 67,039,000 80,981,000
Net Cash Flow, Continuing 63,573,000 -65,008,000 66,997,000 79,268,000
Net Cash Flow From Financing Activities 195,753,000 303,000 2,414,000 231,683,000
Net Cash Flow From Financing Activities, Continuing 195,753,000 303,000 2,414,000 231,683,000
Net Cash Flow From Investing Activities -105,706,000 -71,807,000 32,520,000 -137,623,000
Net Cash Flow From Investing Activities, Continuing -105,706,000 -71,807,000 32,520,000 -137,623,000
Net Cash Flow From Operating Activities -26,474,000 6,496,000 32,063,000 -14,792,000
Net Cash Flow From Operating Activities, Continuing -26,474,000 6,496,000 32,063,000 -14,792,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-29 2021-10-29 2022-02-24
Comprehensive Income/Loss -53,227,000 -39,391,000 -35,523,000 -179,751,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -53,227,000 -39,391,000 -35,523,000 -179,751,000
Other Comprehensive Income/Loss -53,227,000 -39,391,000 -35,523,000 -179,751,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-06 2021-07-29 2021-10-29 2022-02-24
Basic Earnings Per Share -1 -1 -1 -3
Benefits Costs and Expenses 100,961,000 93,580,000 103,813,000 407,172,000
Cost Of Revenue 1,645,000 1,651,000 1,592,000 6,784,000
Costs And Expenses 94,956,000 89,932,000 99,928,000 389,255,000
Diluted Earnings Per Share -1 -1 -1 -3
Gross Profit 45,762,000 52,966,000 66,625,000 220,706,000
Income/Loss From Continuing Operations After Tax -53,867,000 -39,012,000 -35,639,000 -180,091,000
Income/Loss From Continuing Operations Before Tax -53,554,000 -38,963,000 -35,596,000 -179,682,000
Income Tax Expense/Benefit 313,000 49,000 43,000 409,000
Interest Expense, Operating UNPUB UNPUB UNPUB 20,100,000
Net Income/Loss -53,867,000 -39,012,000 -35,639,000 -180,091,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -53,867,000 -39,012,000 -35,639,000 -180,091,000
Net Income/Loss Available To Common Stockholders, Basic -53,867,000 -39,012,000 -35,639,000 -180,091,000
Operating Expenses 93,311,000 88,281,000 98,336,000 382,471,000
Operating Income/Loss -47,549,000 -35,315,000 -31,711,000 -161,765,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 47,407,000 54,617,000 68,217,000 227,490,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-01
Assets UNPUB UNPUB UNPUB 607,439,000
Current Assets UNPUB UNPUB UNPUB 410,407,000
Current Liabilities UNPUB UNPUB UNPUB 92,660,000
Equity UNPUB UNPUB UNPUB 211,213,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Equity Attributable To Parent UNPUB UNPUB UNPUB 211,213,000
Liabilities UNPUB UNPUB UNPUB 396,226,000
Liabilities And Equity UNPUB UNPUB UNPUB 607,439,000
Noncurrent Assets UNPUB UNPUB UNPUB 197,032,000
Noncurrent Liabilities UNPUB UNPUB UNPUB 303,566,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-01
Exchange Gains/Losses UNPUB UNPUB UNPUB -1,307,000
Net Cash Flow UNPUB UNPUB UNPUB 22,336,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB 23,643,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 127,713,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 127,713,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB -61,327,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB -61,327,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -42,743,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -42,743,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-01
Comprehensive Income/Loss UNPUB UNPUB UNPUB -171,059,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -171,059,000
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB -171,059,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2021-03-01
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB 387,111,000
Cost Of Revenue UNPUB UNPUB UNPUB 6,126,000
Costs And Expenses UNPUB UNPUB UNPUB 374,484,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB 192,195,000
Income/Loss From Continuing Operations After Tax UNPUB UNPUB UNPUB -169,431,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB UNPUB -188,790,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB -19,359,000
Interest Expense, Operating UNPUB UNPUB UNPUB 19,050,000
Net Income/Loss UNPUB UNPUB UNPUB -169,431,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Net Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -169,431,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB UNPUB -169,431,000
Operating Expenses UNPUB UNPUB UNPUB 368,358,000
Operating Income/Loss UNPUB UNPUB UNPUB -176,163,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB UNPUB 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB UNPUB 0
Revenues UNPUB UNPUB UNPUB 198,321,000
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:TVTX240517P00015000 OPASPS Put American 100 15 BATO 2024-05-17
O:TVTX240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:TVTX240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:TVTX240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:TVTX240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:TVTX240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:TVTX240517C00015000 OCASPS Call American 100 15 BATO 2024-05-17
O:TVTX240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:TVTX240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:TVTX240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:TVTX240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:TVTX240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:TVTX240419P00015000 OPASPS Put American 100 15 BATO 2024-04-19
O:TVTX240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:TVTX240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:TVTX240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:TVTX240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:TVTX240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:TVTX240419C00015000 OCASPS Call American 100 15 BATO 2024-04-19
O:TVTX240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:TVTX240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:TVTX240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:TVTX240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:TVTX240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:TVTX240315P00030000 OPASPS Put American 100 30 BATO 2024-03-15
O:TVTX240315P00025000 OPASPS Put American 100 25 BATO 2024-03-15
O:TVTX240315P00022500 OPASPS Put American 100 22.5 BATO 2024-03-15
O:TVTX240315P00020000 OPASPS Put American 100 20 BATO 2024-03-15
O:TVTX240315P00017500 OPASPS Put American 100 17.5 BATO 2024-03-15
O:TVTX240315P00015000 OPASPS Put American 100 15 BATO 2024-03-15
O:TVTX240315P00012500 OPASPS Put American 100 12.5 BATO 2024-03-15
O:TVTX240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:TVTX240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:TVTX240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:TVTX240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:TVTX240315C00030000 OCASPS Call American 100 30 BATO 2024-03-15
O:TVTX240315C00025000 OCASPS Call American 100 25 BATO 2024-03-15
O:TVTX240315C00022500 OCASPS Call American 100 22.5 BATO 2024-03-15
O:TVTX240315C00020000 OCASPS Call American 100 20 BATO 2024-03-15
O:TVTX240315C00017500 OCASPS Call American 100 17.5 BATO 2024-03-15
O:TVTX240315C00015000 OCASPS Call American 100 15 BATO 2024-03-15
O:TVTX240315C00012500 OCASPS Call American 100 12.5 BATO 2024-03-15
O:TVTX240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:TVTX240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:TVTX240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:TVTX240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:TVTX240216P00017500 OPASPS Put American 100 17.5 BATO 2024-02-16
O:TVTX240216P00015000 OPASPS Put American 100 15 BATO 2024-02-16
O:TVTX240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:TVTX240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:TVTX240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:TVTX240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:TVTX240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:TVTX240216C00017500 OCASPS Call American 100 17.5 BATO 2024-02-16
O:TVTX240216C00015000 OCASPS Call American 100 15 BATO 2024-02-16
O:TVTX240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:TVTX240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:TVTX240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:TVTX240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:TVTX240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:TVTX240119P00045000 OPASPS Put American 100 45 BATO 2024-01-19
O:TVTX240119P00040000 OPASPS Put American 100 40 BATO 2024-01-19
O:TVTX240119P00035000 OPASPS Put American 100 35 BATO 2024-01-19
O:TVTX240119P00030000 OPASPS Put American 100 30 BATO 2024-01-19
O:TVTX240119P00025000 OPASPS Put American 100 25 BATO 2024-01-19
O:TVTX240119P00022500 OPASPS Put American 100 22.5 BATO 2024-01-19
O:TVTX240119P00020000 OPASPS Put American 100 20 BATO 2024-01-19
O:TVTX240119P00017500 OPASPS Put American 100 17.5 BATO 2024-01-19
O:TVTX240119P00015000 OPASPS Put American 100 15 BATO 2024-01-19
O:TVTX240119P00012500 OPASPS Put American 100 12.5 BATO 2024-01-19
O:TVTX240119P00010000 OPASPS Put American 100 10 BATO 2024-01-19
O:TVTX240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:TVTX240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:TVTX240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:TVTX240119C00045000 OCASPS Call American 100 45 BATO 2024-01-19
O:TVTX240119C00040000 OCASPS Call American 100 40 BATO 2024-01-19
O:TVTX240119C00035000 OCASPS Call American 100 35 BATO 2024-01-19
O:TVTX240119C00030000 OCASPS Call American 100 30 BATO 2024-01-19
O:TVTX240119C00025000 OCASPS Call American 100 25 BATO 2024-01-19
O:TVTX240119C00022500 OCASPS Call American 100 22.5 BATO 2024-01-19
O:TVTX240119C00020000 OCASPS Call American 100 20 BATO 2024-01-19
O:TVTX240119C00017500 OCASPS Call American 100 17.5 BATO 2024-01-19
O:TVTX240119C00015000 OCASPS Call American 100 15 BATO 2024-01-19
O:TVTX240119C00012500 OCASPS Call American 100 12.5 BATO 2024-01-19
O:TVTX240119C00010000 OCASPS Call American 100 10 BATO 2024-01-19
O:TVTX240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:TVTX240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:TVTX240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:TVTX231215P00025000 OPASPS Put American 100 25 BATO 2023-12-15
O:TVTX231215P00022500 OPASPS Put American 100 22.5 BATO 2023-12-15
O:TVTX231215P00020000 OPASPS Put American 100 20 BATO 2023-12-15
O:TVTX231215P00017500 OPASPS Put American 100 17.5 BATO 2023-12-15
O:TVTX231215P00015000 OPASPS Put American 100 15 BATO 2023-12-15
O:TVTX231215P00012500 OPASPS Put American 100 12.5 BATO 2023-12-15
O:TVTX231215P00010000 OPASPS Put American 100 10 BATO 2023-12-15
O:TVTX231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:TVTX231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:TVTX231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:TVTX231215C00035000 OCASPS Call American 100 35 BATO 2023-12-15
O:TVTX231215C00030000 OCASPS Call American 100 30 BATO 2023-12-15
O:TVTX231215C00025000 OCASPS Call American 100 25 BATO 2023-12-15
O:TVTX231215C00022500 OCASPS Call American 100 22.5 BATO 2023-12-15
O:TVTX231215C00020000 OCASPS Call American 100 20 BATO 2023-12-15
O:TVTX231215C00017500 OCASPS Call American 100 17.5 BATO 2023-12-15
O:TVTX231215C00015000 OCASPS Call American 100 15 BATO 2023-12-15
O:TVTX231215C00012500 OCASPS Call American 100 12.5 BATO 2023-12-15
O:TVTX231215C00010000 OCASPS Call American 100 10 BATO 2023-12-15
O:TVTX231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:TVTX231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:TVTX231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:TVTX231215P00035000 OPASPS Put American 100 35 BATO 2023-12-15
O:TVTX231215P00030000 OPASPS Put American 100 30 BATO 2023-12-15
O:TVTX231117P00025000 OPASPS Put American 100 25 BATO 2023-11-17
O:TVTX231117P00022500 OPASPS Put American 100 22.5 BATO 2023-11-17
O:TVTX231117P00020000 OPASPS Put American 100 20 BATO 2023-11-17
O:TVTX231117P00017500 OPASPS Put American 100 17.5 BATO 2023-11-17
O:TVTX231117P00015000 OPASPS Put American 100 15 BATO 2023-11-17
O:TVTX231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:TVTX231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:TVTX231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:TVTX231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:TVTX231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:TVTX231117C00025000 OCASPS Call American 100 25 BATO 2023-11-17
O:TVTX231117C00022500 OCASPS Call American 100 22.5 BATO 2023-11-17
O:TVTX231117C00020000 OCASPS Call American 100 20 BATO 2023-11-17
O:TVTX231117C00017500 OCASPS Call American 100 17.5 BATO 2023-11-17
O:TVTX231117C00015000 OCASPS Call American 100 15 BATO 2023-11-17
O:TVTX231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:TVTX231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:TVTX231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:TVTX231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:TVTX231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:TVTX231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:TVTX231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:TVTX231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:TVTX231020C00030000 OCASPS Call American 100 30 BATO 2023-10-20
O:TVTX231020C00025000 OCASPS Call American 100 25 BATO 2023-10-20
O:TVTX231020C00022500 OCASPS Call American 100 22.5 BATO 2023-10-20
O:TVTX231020C00020000 OCASPS Call American 100 20 BATO 2023-10-20
O:TVTX231020C00017500 OCASPS Call American 100 17.5 BATO 2023-10-20
O:TVTX231020C00015000 OCASPS Call American 100 15 BATO 2023-10-20
O:TVTX231020C00012500 OCASPS Call American 100 12.5 BATO 2023-10-20
O:TVTX231020C00010000 OCASPS Call American 100 10 BATO 2023-10-20
O:TVTX231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:TVTX231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:TVTX231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:TVTX231020P00030000 OPASPS Put American 100 30 BATO 2023-10-20
O:TVTX231020P00025000 OPASPS Put American 100 25 BATO 2023-10-20
O:TVTX231020P00022500 OPASPS Put American 100 22.5 BATO 2023-10-20
O:TVTX231020P00020000 OPASPS Put American 100 20 BATO 2023-10-20
O:TVTX231020P00017500 OPASPS Put American 100 17.5 BATO 2023-10-20
O:TVTX231020P00015000 OPASPS Put American 100 15 BATO 2023-10-20
O:TVTX231020P00012500 OPASPS Put American 100 12.5 BATO 2023-10-20
O:TVTX231020P00010000 OPASPS Put American 100 10 BATO 2023-10-20
O:TVTX230915P00035000 OPASPS Put American 100 35 BATO 2023-09-15
O:TVTX230915P00030000 OPASPS Put American 100 30 BATO 2023-09-15
O:TVTX230915P00025000 OPASPS Put American 100 25 BATO 2023-09-15
O:TVTX230915P00022500 OPASPS Put American 100 22.5 BATO 2023-09-15
O:TVTX230915P00020000 OPASPS Put American 100 20 BATO 2023-09-15
O:TVTX230915P00017500 OPASPS Put American 100 17.5 BATO 2023-09-15
O:TVTX230915P00015000 OPASPS Put American 100 15 BATO 2023-09-15
O:TVTX230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:TVTX230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:TVTX230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:TVTX230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:TVTX230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:TVTX230915C00035000 OCASPS Call American 100 35 BATO 2023-09-15
O:TVTX230915C00030000 OCASPS Call American 100 30 BATO 2023-09-15
O:TVTX230915C00025000 OCASPS Call American 100 25 BATO 2023-09-15
O:TVTX230915C00022500 OCASPS Call American 100 22.5 BATO 2023-09-15
O:TVTX230915C00020000 OCASPS Call American 100 20 BATO 2023-09-15
O:TVTX230915C00017500 OCASPS Call American 100 17.5 BATO 2023-09-15
O:TVTX230915C00015000 OCASPS Call American 100 15 BATO 2023-09-15
O:TVTX230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:TVTX230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:TVTX230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:TVTX230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:TVTX230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:TVTX230818P00035000 OPASPS Put American 100 35 BATO 2023-08-18
O:TVTX230818P00030000 OPASPS Put American 100 30 BATO 2023-08-18
O:TVTX230818P00025000 OPASPS Put American 100 25 BATO 2023-08-18
O:TVTX230818P00022500 OPASPS Put American 100 22.5 BATO 2023-08-18
O:TVTX230818P00020000 OPASPS Put American 100 20 BATO 2023-08-18
O:TVTX230818P00017500 OPASPS Put American 100 17.5 BATO 2023-08-18
O:TVTX230818P00015000 OPASPS Put American 100 15 BATO 2023-08-18
O:TVTX230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:TVTX230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:TVTX230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:TVTX230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:TVTX230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:TVTX230818C00035000 OCASPS Call American 100 35 BATO 2023-08-18
O:TVTX230818C00030000 OCASPS Call American 100 30 BATO 2023-08-18
O:TVTX230818C00025000 OCASPS Call American 100 25 BATO 2023-08-18
O:TVTX230818C00022500 OCASPS Call American 100 22.5 BATO 2023-08-18
O:TVTX230818C00020000 OCASPS Call American 100 20 BATO 2023-08-18
O:TVTX230818C00017500 OCASPS Call American 100 17.5 BATO 2023-08-18
O:TVTX230818C00015000 OCASPS Call American 100 15 BATO 2023-08-18
O:TVTX230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:TVTX230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:TVTX230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:TVTX230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:TVTX230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Financing Agreements
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) --  Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,500 shares of its common stock to five new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,500 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 4d ago
Calendar Calendar of Events
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN
GlobeNewswire Inc. • 1w ago
Calendar Calendar of Events
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Travere Therapeutics Reports First Quarter 2024 Financial Results
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Travere Therapeutics to Report First Quarter 2024 Financial Results
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
GlobeNewswire Inc. • 2w ago
Health Health
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
GlobeNewswire Inc. • 3w ago
Calendar Calendar of Events
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Travere Therapeutics to present abstracts at World Congress of Nephrology and American Nephrology Nurses Association on Rare Kidney Disease
GlobeNewswire Inc. • 1mo ago
News Product / Services Announcement
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 51,600 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 25,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 26,600 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”), but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 2mo ago
Analyst Analyst Ratings
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
Travere Therapeutics (NASDAQ:TVTX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 3 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 1 0 0 2M Ago 0 0 1 0 0 3M Ago 1 0 1 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $13.33, with a high estimate of $20.00 and a low estimate of $9.00. This upward trend is apparent, with the current average reflecting a 9.26% increase from the previous average price target of $12.20. Deciphering Analyst Ratings: An In-Depth Analysis A clear picture of Travere Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ed Arce HC Wainwright & Co. Maintains Buy $17.00 $17.00 Mohit Bansal Wells Fargo Raises Equal-Weight $9.00 $8.00 Laura Chico Wedbush Maintains Outperform $13.00 - Nicole Gabreski Piper Sandler Raises Neutral $11.00 $10.00 Alex Thompson Stifel Raises Hold $10.00 $8.00 Ed Arce HC Wainwright & Co. Raises Buy $20.00 $18.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com
Benzinga • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT